Novartis AG Common Stock (NY:NVS)

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Topics Earnings

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades ↗

Topics Stocks

February 22, 2026

Novartis has a solid portfolio of drugs and a pipeline that should keep the business humming.

Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock with Strong Fundamentals ↗

Topics Intellectual Property

February 19, 2026

Via Chartmill

Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer

February 19, 2026

NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both...

Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too? ↗

A Look Into Novartis Inc's Price Over Earnings ↗

February 17, 2026

Via Benzinga

February 16, 2026

Sprouts Farmers Market runs a national grocery chain focused on fresh, natural, and organic foods for health-conscious shoppers.

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

Topics Regulatory Compliance

February 16, 2026

Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade.

Novartis shared final Phase 3 results showing Vanrafia may slow kidney function decline in adults with IgA nephropathy.

Topics ETFs Stocks

Novartis Says Conditionally Approved Kidney Drug Shows Long-Term Promise ↗

February 13, 2026

Via Benzinga

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

As of February 11, 2026, Incyte Corporation (NASDAQ: INCY) finds itself at a pivotal crossroads. Known for over a decade as a one-drug powerhouse centered on the hematology blockbuster Jakafi, the...

Via Finterra

Topics Economy Intellectual Property

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A...

Topics Intellectual Property

The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map

February 06, 2026

Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse

Topics Artificial Intelligence Economy

February 06, 2026

As of February 6, 2026, Biogen Inc. (NASDAQ: BIIB) stands at a critical crossroads in its nearly 50-year history. Once the undisputed titan of the Multiple Sclerosis (MS) market, the Cambridge-based...

Via Finterra

Topics Earnings Economy Intellectual Property

Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗

February 06, 2026

Arrowhead (ARWR) Q1 2026 Earnings Call Transcript

Novartis (NVS) Q3 2024 Earnings Call Transcript

Topics Earnings

Novartis (NVS) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Novartis AG (NVS) reported Q4 2025 results, with net sales up 1% to $13.34B, missing estimates. Generic competition and pricing impacted sales.

Topics Earnings

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead ↗

February 04, 2026

Via Benzinga

Topics Intellectual Property

Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗

February 03, 2026

Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments.

This Vanguard ETF Has Doubled the S&P 500's Returns Since the Start of 2025. Is It a Buy Now? ↗

Topics Initial Public Offering Intellectual Property Stocks

February 03, 2026

It can be your key to a truly diversified portfolio.

As of early 2026, the promise of “digital-first” drug discovery has shifted from a speculative horizon to a tangible industrial reality. Since its groundbreaking release in May 2024, AlphaFold 3...

Topics ETFs Stocks

Peering Into Novartis AG's Recent Short Interest ↗

February 03, 2026

Via Benzinga

The Biological Singularity: How AlphaFold 3 Is Rewriting the Blueprint of Drug Discovery

February 02, 2026

There are some bargains to be found for dividend investors right now.

Topics Artificial Intelligence

Even Near an All-Time High, This Dividend ETF Looks Extremely Cheap ↗

January 31, 2026

The Biological Singularity: How Nobel-Winning AlphaFold 3 is Rewriting the Blueprint of Life

Topics ETFs

January 28, 2026

In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic...

In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire...

Topics Artificial Intelligence Economy

Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences

January 28, 2026

The Master Architect of Molecules: How Google DeepMind’s AlphaProteo is Rewriting the Blueprint for Cancer Therapy

January 27, 2026

In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a...

If you're worried about U.S. stocks, you might want to load up on some international ones. This ETF makes that easy to do.

Topics Artificial Intelligence

Why I Am Buying the Schwab International Equity ETF (SCHF) and Never Looking Back ↗

January 27, 2026

The Silicon Laureates: How the 2024 Nobel Prizes Rewrote the Rules of Scientific Discovery

Topics ETFs Economy

January 26, 2026

The year 2024 marked a historic inflection point in the history of science, as the Royal Swedish Academy of Sciences awarded Nobel Prizes in both Physics and Chemistry to pioneers of artificial...

Novartis (NVS) is trading at new all-time highs on Monday. Shares are up nearly 50% over the past 52 weeks. NVS maintains a 100% “Buy” technical opinion from Barchart. Novartis has benefitted in recent...

Topics Artificial Intelligence

Is This Pharmaceutical Giant a Winning Tariff-Proof Stock to Buy for 2026?

January 26, 2026

Via Barchart.com

Topics World Trade

International ETFs: SPDW and SCHF Both Offer Low Cost International Exposure ↗

January 24, 2026

Explore how these two leading ETFs differ on risk, yield, and portfolio makeup—key factors for building a balanced global strategy.

These two ETFs will help take your portfolio around the world, with each fund making longer pit stops in certain continents.

Topics ETFs

VWO vs. SPDW: How Does a Emerging Markets ETF Fair Against a Developed World Fund? ↗

January 24, 2026